# ğŸ§¬ CGT æ¯æ—¥æƒ…æŠ¥ (Daily Brief)
> **æ—¥æœŸ**: 2026-02-21 | **æ›´æ–°æ—¶é—´**: 06:50 (åŒ—äº¬æ—¶é—´)
> **ç›‘æ§èŒƒå›´**: Global (In vivo/FDA) & China (NMPA/Biotech)

---

## ğŸŒ å…¨çƒå‰æ²¿ (FDA / In vivo / MNCs)
- `[21:30]` **ImmunityBio ä¸ Biopharma å’Œ Cigalah Healthcare åˆä½œï¼Œåœ¨æ²™ç‰¹é˜¿æ‹‰ä¼¯ä¸ºè†€èƒ±ç™Œå’Œè‚ºç™Œæ‚£è€…æ¨å‡º ANKTIVAÂ®**
  <br><small>ğŸ‡¬ğŸ‡§ *ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVAÂ® in Saudi Arabia for Bladder and Lung Cancer Patients* [ğŸ”—Source](https://news.google.com/rss/articles/CBMilAJBVV95cUxQcTJpMmYzOEsya3VSOXRJelVqOFZEaERHS0lOOVVhc19nNFJZZ2h1M3NaTUpycjFiRkNVT2kzMkpzNjRCQXJoTDZFVjVZSVQ3bmtrTEhtamhVSURkM3J0V1phclR0aElOWU1kRmJoVHc1dVFLQkd6MnhkQXF6QzZoY3UtRTBqMkVuYWdJWm0zQ0RuTkp6amxZSjMxeENZbklQQzBwbXhpbDhvbmgybWI2QUJpd182ZHpYTXplZHI5QmZUSmFUM3pjYVlLZE1MMFExaHI3a0tJNkw0ekRONjRaSkJrSTZQMVNqdFQyY0ZqNDBDR0R2YnVnYzVTeHh1UDBFdHg2T0hxdWxZWGg3QUlyNnFCR08?oc=5)</small>
- `[15:00]` **ğŸ›ï¸ç›‘ç®¡ | ç¾å›½é£Ÿå“å’Œè¯ç‰©ç®¡ç†å±€ (FDA) æ‰¹å‡† VENCLEXTAÂ® (venetoclax) å’Œ Acalabrutinib è”åˆæ²»ç–—å…ˆå‰æœªç»æ²»ç–—çš„æ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—… (CLL) æ‚£è€…**
  <br><small>ğŸ‡¬ğŸ‡§ *U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTAÂ® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)* [ğŸ”—Source](https://news.google.com/rss/articles/CBMi1wJBVV95cUxPeWJvT1dzNlFOaUEyNHpWMVY5UmpzLV9WYy13TFVLWDh5aTRHazV0QUlhalBHQnJ0NktpTG1IMk9PSnBoODNaUkJtLTIxb0dDZU9jZ1N3enRKQlF6U2FZUFRjSFZ0R0ZSSUF2dUtRaGV3WFhXTDVidTZqT0cwSl9jSVlxOTYzTWEzZ1A4cFVmQS13U1BzTU1JMlE4STlIZlIwM1BzQTJxZTNIZEZqa2t5dXJ3NkE1NHZxUy1EdEs0VVpfcnZVTXh3QlNhNmdZNWF6RWVlbFdFUkpoSU1IVHN4bE9DSG9HMUtUM21IUXRCNmFqNm9jSURwN0RhRXdtdzduRkVLNXlEeURJdkFEMW5lWldEUE9GbTRXRllvYndISnIxb3RLdi1YenpHZVl4ZHZjVHVOOU9SZEdBbVBfalk4bmVGdHZmMkM5SFpGaXFScWRYby0wQXhN?oc=5)</small>

---

## ğŸ‡¨ğŸ‡³ ä¸­å›½åŠ¨æ€ (NMPA / Domestic Players)
- `[05:02]` **iRegene åˆ›ä¸‹å…¨çƒä¸¤é¡¹ç¬¬ä¸€ï¼šNouvNeu001 æ²»ç–—å¸•é‡‘æ£®ç—…çš„ IIa æœŸç¾å›½æ‚£è€…æ¥å—ç»™è¯ï¼Œä»¥åŠ NouvNeu004 åœ¨ä¸­å›½éšæœº MSA è¯•éªŒä¸­é¦–æ¬¡å…¥ç»„**
  <br><small>ğŸ‡¬ğŸ‡§ *iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinsonâ€™s and First Enrollment in Chinaâ€™s Randomized MSA Trial for NouvNeu004* [ğŸ”—Source](https://news.google.com/rss/articles/CBMiwgFBVV95cUxNb005SFZBMkk0TElwXzgtX3RwMzBMLUNtZTFfYXl6S0MzeHNLaWpMOUI1cXY1UVNGMm9TVlRPUFoxODNKb1E0QkJ1ZURQR3h0QXI2dDlvelpfVzNLNU9wR1hZUllEYWpGVEI4OGtrY2xEYmNGQVR6QktjcWt2RmRObnNFMjJhVkM0UzVmVktlVHFRejJITmZ3ZDRvbzFyQk5nRV9Kc293cGl6UjJiZmdhTDFDYmNJam5jcE9uMXdJSl9zUQ?oc=5)</small>
- `[00:12]` **Fierce Pharma Asiaâ€”â€”å‰åˆ©å¾·çš„åˆæˆè‡´æ­»äº¤æ˜“ï¼›ä¸œäº¬ç”Ÿç‰©ç§‘æŠ€å…¬å¸é¦–æ¬¡å…¬å¼€å‹Ÿè‚¡ï¼› Novo Ozempic ä¸­å›½é”€å”®é¢ä¸‹æ»‘**
  <br><small>ğŸ‡¬ğŸ‡§ *Fierce Pharma Asiaâ€”Gilead's synthetic lethality deal; A Tokyo biotech IPO; Novoâ€™s Ozempic China sales dip* [ğŸ”—Source](https://news.google.com/rss/articles/CBMitgFBVV95cUxNM2RJUWlYazZodWVMUmt6TW84UUZRZGZpREMxaGJzLUpoZ242U2tta0w1SEZsNFpQdzZNUTZCU3lIU0o5b2JzYlNjY01iaFB1TzBQZ1pvcGxqQzEwZkxZaEpxTWFQNV9uVnMzZUFQVktRLW1kU3BqWWZYTUJoUTViVnYwNk1FQlR1SmxKOFh4dFBjT25oZkZsTE0zbmc4X2tnc194Q3NLVFcyMHRqUHE1ZVdrYlJJQQ?oc=5)</small>
